Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with revenue growth and significant debt reduction, alongside strategic investments in R&D and sales force expansion. The Q&A section highlights management's focus on growth and innovation, with positive sentiment from analysts. Despite some uncertainties in management responses, the overall outlook is optimistic with potential for market expansion and partnerships. This suggests a positive stock price movement over the next two weeks.
Key Financial Performance
LOQTORZI net revenue for 2025 $40.8 million, representing a 113% growth year-over-year from $19.1 million in 2024. The growth was driven by new patient starts, increased purchasing accounts, and updated NCCN guidelines positioning LOQTORZI as the preferred treatment for recurrent and metastatic NPC.
Q4 2025 LOQTORZI net revenue $12.4 million, an 11% growth over Q3 2025. The growth was driven by a 15.5% quarter-over-quarter demand increase, although offset by wholesaler inventory declines.
Debt reduction Reduced from $480 million in 2024 to $38.8 million by the end of 2025, a 90% reduction. This was achieved through divestitures and operational efficiencies, significantly reducing interest costs.
Headcount reduction Reduced from 228 at the end of 2024 to 147 at the end of 2025, a 35% reduction. This was part of the company’s transformation strategy to focus on innovative oncology.
SG&A expenses for Q4 2025 $23.6 million, down from $29.6 million in Q4 2024. The decrease was due to reduced headcount, exiting biosimilars, and spending discipline.
R&D expenses for Q4 2025 $31 million, up from $20.8 million in Q4 2024. The increase reflects investments in Coherus's oncology pipeline.
Cash equivalents and investments at year-end 2025 $172.1 million. This includes a $50 million follow-on offering to support pipeline development and commercial investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
LOQTORZI launch: Launched in 2024 as a next-gen PD-1 inhibitor for recurrent, locally advanced, or metastatic Nasopharyngeal Carcinoma (NPC) in the U.S., addressing a $250 million market. Sales more than doubled in 2025 compared to 2024, reaching $40.8 million.
Pipeline products: Tagmokitug and Casdozokitug are two promising assets acquired through the Surface Oncology acquisition. Tagmokitug is a CCR8 Treg cell depleter, and Casdozokitug is an anti-IL-27 inhibitor. Both are undergoing clinical trials with potential registration trials in 2027.
Market share for LOQTORZI: Expected to achieve 70% market share of the $250 million NPC market by 2028, corresponding to $175 million in annualized revenues.
Expansion in Veterans Affairs hospitals: Specialized team engaged to access VA hospitals, which are typically hard to reach, to expand LOQTORZI's reach.
Debt reduction: Reduced secured and convertible debt by over 90% from $480 million to $38.8 million by the end of 2025.
Headcount reduction: Reduced headcount by approximately 35%, from 228 in 2024 to 147 in 2025, as part of the strategic transformation.
Revenue growth: LOQTORZI net revenue grew by 113% year-over-year, from $19.1 million in 2024 to $40.8 million in 2025.
Strategic transformation: Transitioned from a biosimilar company to an innovative oncology company focused on overcoming immune resistance in cancer. This included the acquisition of Surface Oncology and divestiture of the biosimilar franchise.
Partnerships and collaborations: Established a collaboration with Johnson & Johnson to study the combination of Tagmokitug with a T-cell engager for prostate cancer. Exploring additional partnerships for global opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Competition: The Treg field is increasingly competitive, with expected data readouts by other parties this year, which could impact the company's market position and differentiation.
Regulatory and Clinical Risks: The company is reliant on successful clinical trials for its pipeline products, including tagmokitug and casdozokitug. Delays or failures in these trials could adversely affect strategic objectives and financial performance.
Financial Sustainability: The company is dependent on LOQTORZI sales to fund operations and pipeline development. Any underperformance in LOQTORZI sales could impact the company's ability to sustain operations and fund clinical trials.
Supply Chain and Operational Risks: The company has reduced headcount and expenses significantly, which may strain operational capacity and efficiency, potentially impacting execution of strategic objectives.
Partnership and Deal Risks: The company is reliant on partnerships and external funding to offset pivotal trial costs. Failure to secure these partnerships or funding could increase financial strain.
Economic and Market Uncertainty: The company operates in a rare disease market with limited addressable market size, which could limit revenue growth potential and expose the company to economic fluctuations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections for LOQTORZI: LOQTORZI is expected to achieve peak market share in 2028, corresponding to $175 million in annualized revenues or about 70% market share of the $250 million market total. The company anticipates reaching $15-$16 million in quarterly sales by 2026, at which point the commercial effort will pay for itself. By 2027, quarterly revenues of $30-$35 million are expected to cover the company's core burn.
Funding and Financial Position: The company recently raised $50 million to support commercial efforts and invest in the tagmokitug clinical program. Coherus believes it is sufficiently funded through key data readouts in 2026 and into 2027. The company also expects to earn two sales milestones of $37.5 million each based on UDENYCA sales criteria by Q3 2026 and Q1 2027.
Clinical Development Timelines: Initial data readouts for tagmokitug and casdozokitug are expected from mid-2026 onwards. The tagmokitug pasritamig combination study in metastatic prostate cancer is anticipated to start in the second half of 2026.
Market Opportunity for LOQTORZI: LOQTORZI is positioned as the only preferred treatment for recurrent and metastatic nasopharyngeal carcinoma (NPC) in the U.S., with a $250 million addressable market. The company expects average quarter-over-quarter demand growth of 10%-15% in 2026.
Pipeline Development: The company is advancing two key product candidates, tagmokitug and casdozokitug, with multiple clinical trials underway. Tagmokitug is being positioned as a Treg depleter of choice across cancer treatments, while casdozokitug is focused on tissue cancers such as liver and lung. Both programs are expected to provide initial data readouts in 2026.
Strategic Partnerships: Coherus is exploring ex-U.S. partnership opportunities for tagmokitug and casdozokitug, with expectations of upfront payments and cost-sharing for pivotal trials. The company has initiated a collaboration with Johnson & Johnson to study the combination of tagmokitug with pasritamig in metastatic prostate cancer.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the dynamic between new patient starts and repeat patients for LOQTORZI in 2025 and how this balance might shift in 2026?
A:In 2025, approximately 25% of the business came from new patients, with the rest from continuing patients. The mix is expected to shift slightly more towards new patients due to growth opportunities, while existing patients will remain a strong base as therapy duration increases.
Q:What is the promotional sensitivity of LOQTORZI and details on commercial infrastructure investments?
A:LOQTORZI is highly promotion-sensitive as physicians need continuous reminders about its benefits. A 15% field force expansion was done, with 4 inside sales representatives added to target tier 2 areas and a VA-targeted contract sales force. Investments were also made in IT infrastructure, increasing diagnosis code alert capture from 30-35% to 65-70%, and enhancing sales team dashboards.
Q:Are there plans for exploring a triple combination with Tagmo in prostate cancer?
A:The company is watching results from studies like J&J's phase I combo data. The first step is combining two drugs to assess safety and efficacy before considering earlier lines or other combinations.
Q:Is the frontline HCC trial for casdozokitug randomized but not blinded, and are responses being tracked?
A:The trial is open-label, and responses will be reported when mature. Previous studies showed data maturation over time with increased response rates and deeper responses.
Q:How will data for Tagmokitug in various tumor types be disclosed?
A:Data disclosure depends on patient numbers and scan availability. If timing aligns with congress submission deadlines, data will be released at a congress; otherwise, it will be disclosed via corporate announcements.
Q:What is the maturation timeline for the casdozo frontline HCC study, and what bar is set for the early readout?
A:The maturation timeline is 6-12 months, with several data cuts showing increased response rates over time. The bar for early readout is an overall response rate above the current standard of care (30% for Atezo/Bev).
Q:What are the important updates on the competitive front for CCR8 this year, and how might they impact development strategy?
A:Updates from major players with large patient studies are expected. BMS has CCR8 on its launch map by the end of the decade. The company is focusing on durability, safety, and overall clinical benefit rate in its program.
Q:What is the strategy for developing a prostate cancer combo with Tagmo and Pasri, and what is the bar for PSA50 in mCRPC?
A:The strategy prioritizes data across tumor types with strong scientific rationale. For PSA50 in mCRPC, benchmarks are 70% in first line, 45% in second line, and 20% or less in third line. Safety and PSA50 are key metrics.
Q:What is the framework for R&D spending and balancing revenues with additional capital needs?
A:R&D spending is categorized separately from commercial and SG&A costs. The company is strategically pursuing trials and partnerships, such as with J&J, while maintaining financial discipline. Revenue growth is expected to support R&D without additional capital needs.
Q:What is the current duration of therapy for LOQTORZI, and is there room for improvement?
A:Duration of therapy varies by indication and continues to grow based on claims data. The company is not ready to provide an average duration but sees room for growth to match clinical trial durations.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the average duration of therapy for LOQTORZI, citing insufficient patient data. They also did not comment on specific expectations for PSA50 in mCRPC beyond general benchmarks.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Atezo
CRC
CRPC
Catalyze program
Coherus Oncology
Cohort line
GI adeno
JJ
Johnson
PD resistance
TCE
TCEs
TSA
Tagmo combination
activation cell
combination partner
combination study
context
core burn
debt
depleter
dos Tagmo
effort
example
field
insight
investor
liability
mechanism action
milestone quarter
pasritamig
prostate cancer
protocol
reduction
start
tier
transaction
tumor cell
tumor treatment
utility
CHRS Transcript
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call reveals a mixed outlook. While there's optimism with strategic partnerships and robust new patient starts, concerns arise from weather impacts on revenue and management's vague responses in the Q&A. The company's strong funding position and pipeline developments are positives, but uncertainties about treatment transitions and competitive pressures in the clinical space temper enthusiasm. Without clear financial guidance or market cap data, the stock reaction is likely to remain neutral, with limited short-term catalysts to drive significant price movement.
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Positive3-9
The earnings call reveals strong financial performance with revenue growth and significant debt reduction, alongside strategic investments in R&D and sales force expansion. The Q&A section highlights management's focus on growth and innovation, with positive sentiment from analysts. Despite some uncertainties in management responses, the overall outlook is optimistic with potential for market expansion and partnerships. This suggests a positive stock price movement over the next two weeks.
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-10
CHRS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
